Host modulation therapy: An updated review

Ipshita, Sahu; Kurian, Ida Grace; Dileep, Pankaj; Guruprasad, C. N.; Singh, Priyanka; Pradeep, A.R.

doi:10.15713/ins.jcri.157

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arachidonic acid metabolites modulation: Prostaglandins (PGs) are one of the most crucial mediator in periodontitis for bone loss. 12 PGs are metabolized via the cyclooxygenase (COX) route, and leukotrienes via the lipoxygenase (LOX) pathway, resulting in unbound AA. 12,13 2.…”

Section: Targets F O R Host Modulatory Agentsmentioning

confidence: 99%

Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective

Mahajan,

Chandel,

Asi

et al. 2024

Dental Journal of Advance Studies

View full text Add to dashboard Cite

As our basic knowledge of the etiopathogenesis of periodontitis has improved over the past years, it has become evident that the periodontal disease is multifactorial disease caused by the bacteria which establishes the immune reaction in the host. This initiation of the host response leads to destruction of the surrounding periodontium which ultimately results in tooth loss. An ever-increasing research in the field of pathogenesis of periodontitis has revealed that the initial breakdown in chronic inflammatory periodontal disease often involves a failure of resolution pathways in order to restore host's homeostasis. The practice of modulating the host response to control periodontal disease has been employed for many years not only for the periodontal disease but also for various medical conditions. As a result, the goal of this review is to provide an overview of existing findings on host modulation therapies (HMTs). In addition, to describe some of the recent advances made over the years in the field of HMTs and to determine some pertinent conclusions about its involvement in disease development and its use in clinical therapy. This will provide a chance for more detailed investigation in this particular field. As a result, the goal of this review is to describe the current findings available in the literature on HMT.

show abstract

Section: Targets F O R Host Modulatory Agentsmentioning

confidence: 99%

Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective

Mahajan,

Chandel,

Asi

et al. 2024

Dental Journal of Advance Studies

View full text Add to dashboard Cite

show abstract

“…Future prospect lies for chemically modified tetracycline (CMT's), bone resorption uncouplers, anti-cytokine drugs, antimetabolites, and lipoxins (LXs). This provides clinician with supplementary equipment to conventional mechanical debridement, which could improve and make the clinical therapeutic outcome more predictable, in a susceptible host [9] . In addition, a number of local host modulatory agents have been investigated in clinical trials for their potential use as adjuncts to surgical procedures not only to improve upon wound healing but also to stimulate regeneration of lost bone, periodontal ligament, and cementum, restoring the complete periodontal attachment apparatus.…”

Section: Host Modulationmentioning

confidence: 99%

Host modulation as a therapeutic strategy

Gaind¹,

Khatri²,

Bansal³

et al. 2021

Int. J. Appl. Dent. Sci.

View full text Add to dashboard Cite

Periodontal diseases are bacterial-induced inflammatory disease characterized by a complex interplay between the pathogens and the host tissue. A disturbance in the equilibrium between bacteria and host, results in periodontal tissue destruction. As periodontal disease progresses, a series of events occur in bacterial plaque, gingival sulcus, junctional epithelium, connective tissue, and bone, due to alteration in tissue homeostasis. This increasing awareness and knowledge of the host microbial interaction in periodontal pathogenesis has presented the opportunity for exploring new therapeutic strategies for periodontitis by means of targeting host response via host modulating agents. This has lead to the emergence of the field of "Perioceutics" i.e. the use of pharmacotherapeutic agents including antimicrobial therapy as well as host modulatory therapy for the management of periodontitis. These host modulating agents used as an adjunct tip the balance between periodontal health and disease progression in the direction of a healing response.

show abstract

“…However, with numerous NSAIDs emerging and proving their positive association in the treatment of periodontitis, the risk of significant unwanted effects precluded their use. [ 4 ] As of now, to date, subantimicrobial-dose doxycycline is the only available adjunctive host response modulator that is licensed for the treatment of periodontitis. Due to this inhibitory action on matrix metalloproteinases, its clinical benefits in randomized controlled clinical trials have yet to be determined.…”

Section: Introductionmentioning

confidence: 99%

Role of Orthoboon (glucosamine sulfate + collagen + Vitamin C): A novel host-modulating agent in the management of chronic periodontitis

Penmetsa

Mopidevi

Ramaraju

et al. 2020

J Indian Soc Periodontol

View full text Add to dashboard Cite

Background: Recent trends suggest using novel host-modulating agents as a treatment strategy for chronic periodontitis. Glucosamine sulfate (GS) was proven to have anti-inflammatory actions related to its ability to suppress neutrophil functions. Orthoboon, an anti-arthritic and anti-inflammatory drug, has shown to have a positive therapeutic effect due to its constituents made of a combination of GS, Vitamin C, and collagen. The aim of the study was to evaluate the host modulatory effects of Orthoboon on periodontal status and to estimate the C reactive protein (CRP) levels before and after nonsurgical periodontal therapy (NSPT). Materials and Methods: A total number of 40 patients with chronic periodontitis were randomly divided into two groups of 20 patients each. The test group patients ( n = 20) received 500 mg Orthoboon three times daily for 45 days. Prior to the initiation of Orthoboon, all patients in both test group and control group were subjected to Phase I periodontal therapy. CRP levels were estimated immediately after phase I therapy and 45 days after therapy. Clinical parameters including plaque index, gingival index, and bleeding index were recorded before and after NSPT for the two groups. Results: The mean CRP levels were reduced significantly in the test group before and after administration of Orthoboon and also there were statistically significant differences in the mean CRP levels at the end of 45 days between the test group and the control group. Conclusion: Administration of Orthoboon, i.e., GS, with a combination of Vitamin C and collagen was proved to be of a significant benefit in the test group than in the control group.

show abstract

Host modulation therapy: An updated review

Abstract: Chronic periodontitis is a polymicrobial inflammatory disease of multifactorial origin.

Cited by 4 publications

References 26 publications

Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective

Managing Periodontitis with Host Modulation Therapy: Current Concept and Future Perspective

Host modulation as a therapeutic strategy

Role of Orthoboon (glucosamine sulfate + collagen + Vitamin C): A novel host-modulating agent in the management of chronic periodontitis

Contact Info

Product

Resources

About